Halifax-based Sona Nanotech has announced that strategic adviser David Regan will replace Darren Rowles as CEO and that it will pursue a listing on the NASDAQ stock exchange in New York.
Sona has been a darling of the Canadian Securities Exchange since it said in March it would use its nanoparticle technology to develop rapid diagnostic kits for diseases that include COVID-19. The share price has soared since it said last week its coronavirus test would enter production with a “research use only” disclaimer as it sought approval from the Food and Drug Administration and Health Canada.
The